Polarean Imaging Partners with Ascend Imaging to Accelerate US Sales

The Leadership Perspective

Both sides are understandably bullish about the collaboration:

• Alan Huang, Ph.D., VP of Sales, Polarean: “We are pleased to welcome Ascend Imaging as a strategic sales partner… This partnership enhances our reach in key US regions while maintaining operational efficiency, and we expect it to support meaningful commercial momentum in the second half of 2025 and beyond.” (Note the clear expectation for H2 2025 impact).
• Wesley Adams, President, Ascend Imaging: “We are excited to partner with Polarean to help bring their groundbreaking Xenon MRI technology to more healthcare providers… We look forward to expanding access to this important imaging innovation.”

Polarean’s Game: Revolutionising Lung Imaging

A quick recap on why Polarean matters: They’re pioneers in functional MRI of the lungs. Their FDA-approved XENOVIEW® platform uses hyperpolarised Xenon gas as a safe, non-invasive, radiation-free contrast agent. This allows clinicians to directly visualise lung ventilation – seeing *how well* air is moving through the lungs – a significant leap forward for diagnosing and managing chronic respiratory diseases affecting hundreds of millions globally.

They are a rare beast: a commercial-stage AIM company with an approved, innovative medical product actively seeking market penetration.

What This Deal Signals

This agreement is a pragmatic and potentially savvy move by Polarean:

• Accelerated Market Access: Leveraging Ascend’s existing relationships bypasses the slow process of building a massive direct sales force from scratch in every target region.
• Cost-Effective Scaling: Using independent reps allows Polarean to scale its commercial efforts in specific geographies without the full fixed costs of direct employees.
• Validation: That a specialised player like Ascend sees value and opportunity in Polarean’s technology is a positive signal.
• Focus on Execution: It underscores management’s focus on converting its FDA approval into tangible sales and market presence, particularly within the vast US healthcare market.

The proof, as ever, will be in the pudding – or rather, in the sales figures and updates on installations facilitated through this channel later in 2025. But strategically, this looks like a solid step on Polarean’s commercial journey.